Home
/
UroGen Pharma Ltd.
/
Financials
/
Quarterly
UroGen Pharma Ltd. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that UroGen Pharma Ltd. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$27.48M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$24.22M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$20.25M
May 12, 2025
Q3
2025
Sep 30, 2024
$25.20M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$21.85M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$18.78M
May 12, 2025
Q3
2024
Sep 30, 2023
$20.85M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$21.14M
Aug 13, 2024
Q1
2024
Mar 31, 2023
$17.19M
May 13, 2024
Q3
2023
Sep 30, 2022
$16.10M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$16.60M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$13.56M
May 11, 2023
Q3
2022
Sep 30, 2021
$11.35M
Nov 10, 2022
Q2
2022
Jun 30, 2021
$13.03M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$7.49M
May 10, 2022
Q3
2021
Sep 30, 2020
$3.46M
Nov 15, 2021
Q2
2021
Jun 30, 2020
$372.0K
Aug 4, 2021
Q3
2020
Sep 30, 2019
$18.0K
Nov 9, 2020
Q2
2020
Jun 30, 2019
$18.0K
Aug 10, 2020
Q3
2019
Sep 30, 2018
$283.0K
Nov 12, 2019
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($33.35M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($49.94M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($43.84M)
May 12, 2025
Q3
2025
Sep 30, 2024
($23.67M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($33.40M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($32.29M)
May 12, 2025
Q3
2024
Sep 30, 2023
($21.88M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($24.14M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($30.21M)
May 13, 2024
Q3
2023
Sep 30, 2022
($25.83M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($26.69M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($28.39M)
May 11, 2023
Q3
2022
Sep 30, 2021
($30.21M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($26.22M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($25.94M)
May 10, 2022
Q3
2021
Sep 30, 2020
($28.82M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($31.35M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($37.79M)
May 13, 2021
Q3
2020
Sep 30, 2019
($22.25M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($22.48M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($27.39M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($41.45M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($36.91M)
May 12, 2025
Q3
2025
Sep 30, 2024
($17.55M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($25.84M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($25.74M)
May 12, 2025
Q3
2024
Sep 30, 2023
($13.50M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($15.38M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($22.05M)
May 13, 2024
Q3
2023
Sep 30, 2022
($18.09M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($18.72M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($21.96M)
May 11, 2023
Q3
2022
Sep 30, 2021
($23.44M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($22.82M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($26.11M)
May 10, 2022
Q3
2021
Sep 30, 2020
($29.12M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($31.80M)
Aug 4, 2021
Q1
2021
Mar 31, 2020
($38.56M)
May 13, 2021
Q3
2020
Sep 30, 2019
($23.45M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($23.75M)
Aug 10, 2020